Top Medical News
12 hours ago
Levels of fibroblast growth factor (FGF)-21, an adipokine linked to metabolic stress, correlate with obesity and inflammatory cytokines, as well as with worsening physical functioning in patients with rheumatoid arthritis (RA), suggests a study.
5 days ago
Among systemic lupus erythematosus (SLE) patients with musculoskeletal symptoms, those who have positive ultrasound appear to show better response to therapy, a study reports.
10 Apr 2021
Engaging in higher levels of physical activity seems to protect against the risk of developing rheumatoid arthritis (RA), although this relationship is not causal, according to a Mendelian randomization analysis.
Jairia Dela Cruz, 07 Apr 2021
Secukinumab, at both 300 and 150 mg, scores high in the management of psoriatic arthritis (PsA) patients with axial manifestations and inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs), as shown in the results of the phase III MAXIMISE trial.
07 Apr 2021
Among young adults with hypertension, treatment with the urate-lowering drug allopurinol appears to improve endothelial function, although this does not translate to meaningful reductions in blood pressure or inflammation levels, as shown in a study.
Jairia Dela Cruz, 03 Apr 2021
Low disease activity (LDA) and remission in women with rheumatoid arthritis (RA) can be easily achieved during pregnancy with the help of a modified treat-to-target (T2T) approach that incorporates the use of tumour necrosis factor inhibitors (TNFIs), as shown in the PreCARA* study.
Elvira Manzano, 05 Aug 2020
The US FDA has given secukinumab the greenlight for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA), following its success in the phase III PREVENT trial, the largest ever for a biologic in nr-axSpa.
Audrey Abella, 21 Jul 2020
The IL-1 receptor antagonist anakinra – a drug for rheumatoid arthritis – demonstrated potential in treating gout, as it reduced gout pain and flares to similar degrees as triamcinolone, results of the ANAGO* study have shown.
Pearl Toh, 20 Jul 2020
The investigational interleukin (IL)-6 inhibitor olokizumab is effective in improving symptoms and physical function of patients with moderate-to-severe rheumatoid arthritis (RA) who are inadequately controlled with methotrexate (MTX), according to the CREDO-1 study presented at the EULAR 2020 Virtual Meeting.
Audrey Abella, 20 Jul 2020
Use of the monoclonal antibody ixekizumab led to improvements in symptoms, work productivity, and overall functioning and health in patients with nonradiographic axial spondyloarthritis (nr-axSpA), subgroup results of the phase III COAST-X trial have shown.
Audrey Abella, 15 Jul 2020
The type I interferon receptor antibody anifrolumab reduced disease activity and flares in patients with moderate-to-severe active systemic lupus erythematosus (SLE), results of the TULIP-1 and TULIP-2 trials have shown.
Elaine Soliven, 15 Jul 2020
Treatment with tanezumab, a monoclonal antibody against nerve growth factor, significantly reduces pain intensity and improves daily function in patients with chronic low back pain, according to a trial presented at EULAR 2020.
Audrey Abella, 09 Jul 2020
The anti-interleukin 17A antibody netakimab reduces disease activity and skin manifestations in patients with active psoriatic arthritis (PsA), consequently improving patient-reported outcomes (PROs), analyses of the phase III PATERA trial have shown.